SEC Form 4 · accession 0001513162-17-000253
Anixa Biosciences Inc · ANIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Kumar
Officer — Chief Executive Officer · Director
Period of report
Sep 6, 2017
Accepted (ET)
Sep 8, 2017 · 5:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000715446
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF1,F2 | $2.575 | Sep 6, 2017 | D | 320,000 | D | — | Sep 19, 2022 | Common Stock | 320,000 | 0 | D |
| Employee Stock OptionF1,F2 | $0.67 | Sep 6, 2017 | A | 320,000 | A | — | Sep 19, 2022 | Common Stock | 320,000 | 320,000 | D |
| Employee Stock OptionF1,F3 | $2.575 | Sep 6, 2017 | D | 106,667 | D | — | Sep 19, 2022 | Common Stock | 106,667 | 0 | D |
| Employee Stock OptionF1,F3 | $0.67 | Sep 6, 2017 | A | 106,667 | A | — | Sep 19, 2022 | Common Stock | 106,667 | 106,667 | D |
| Employee Stock OptionF1,F3 | $2.575 | Sep 6, 2017 | D | 213,333 | D | — | Sep 19, 2022 | Common Stock | 213,333 | 0 | D |
| Employee Stock OptionF1,F3 | $0.67 | Sep 6, 2017 | A | 213,333 | A | — | Sep 19, 2022 | Common Stock | 213,333 | 213,333 | D |
| Employee Stock OptionF1,F4 | $2.575 | Sep 6, 2017 | D | 40,000 | D | — | Nov 8, 2023 | Common Stock | 40,000 | 0 | D |
| Employee Stock OptionF1,F4 | $0.67 | Sep 6, 2017 | A | 40,000 | A | — | Nov 8, 2023 | Common Stock | 40,000 | 40,000 | D |
| Employee Stock OptionF1,F5 | $2.92 | Sep 6, 2017 | D | 200,000 | D | — | Feb 18, 2026 | Common Stock | 200,000 | 0 | D |
| Employee Stock OptionF1,F5 | $0.67 | Sep 6, 2017 | A | 200,000 | A | — | Feb 18, 2026 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1These transactions involved an amendment of outstanding stock options for the sole purpose of lowering the exercise price, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options.
- F2The option was originally granted on September 19, 2012 and vested in 36 equal monthly installments beginning on October 31, 2012.
- F3The option was originally granted September 19, 2012 and vested as follows: (i) 106,667 shares upon the achievement of certain performance criteria; and (ii) 213,333 shares in two equal installments if the average closing price of the Company's common stock exceeds certain specified levels.
- F4The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013.
- F5The option was originally granted on February 18, 2016 and vested in 36 consecutive monthly installments beginning on March 31, 2016.